Peripheral Vascular Stents

The market for stents used in peripheral vascular indications — inclusive of stent grafts, and arterial and venous stents — is growing at an aggregate 6.2% CAGR from 2016 to 2020, which belies much stronger growth in specific subsets, especially in emerging markets like Asia/Pacific.

The aggregate compound growth rates for peripheral stent markets in each global region is shown below, with growth rates weighted by individual segment sales:

U.S.:  9.5%
Western Europe: 5%
Asia/Pacific: 21.3%
Rest of World: 13.9%

Peripheral stent products include the following, each of which is growing in sales at varying rates above and below the aggregregate regional sales growth:

Peripheral Arterial Stenting

– Bare Metal Stent Devices

– Drug Eluting Stent Devices

Aortic Aneurysm Repair

– Abdominal AA Stent-Grafts

– Thoracic AA Stent-Grafts

Peripheral Venous Stents

 

Worldwide Peripheral Stent Market by Product Category, 2015 and 2020

Screen Shot 2016-08-08 at 12.49.53 PM

Source: MedMarket Diligence, LLC; Report #V201.

Transcath and surgical cardio volumes trending

VasculatureInterventional devices, offering MIS advantages, have preempted surgical caseload, and have expanded the treatable patient population. Multiple competitive alternatives are effective for high volume procedures for treatment of coronary artery, peripheral artery and other cardiovascular pathologies.

Clinicians have changing demands, sometimes very much in alignment with what manufacturers see as needs (it is good to point out their need before they see it).

Older populations are good for medtech — let’s be honest. (Yes, the “aging demographic” argument has been made again, but it is particularly true for interventional procedures, which are used disproportionately in older populations in accordance with age-based incidence rates in cardiovascular disorders.)

Cardio device manufacturers both lead and follow the market. Technologies that lower invasiveness, reduce complications, reduce repeats, increase outcomes, lower costs, and provide other benefits drive new procedure volume. When new technologies are progressively introduced, they have variable impacts on procedure volume, either displacing caseload or tapping new. The timing and relative impact of new technology emerging can cause abrupt shifts in caseload, procedures — and revenue.

Here are the top procedures for surgical and interventional cardiology:

  • Coronary artery bypass grafting
  • Coronary angioplasty and stenting coronary/mechanical and laser atherectomy
  • Ventricular assist device placement
  • Total artificial heart implantation
  • Donor heart transplantation
  • Lower extremity arterial bypass surgery
  • Percutaneous transluminal angioplasty (PTA) and bare metal stenting
  • PTA and drug-eluting stenting
  • PTA with coated balloons
  • Mechanical and laser atherectomy
  • Catheter-directed thrombolysis and thrombectomy
  • Aortic aneurysm repair
  • Vena cava filter placement
  • Endovenous ablation
  • Mechanical venous thrombectomy
  • Venous angioplasty and stenting
  • Carotid endarterectomy
  • Carotid artery stenting
  • Cerebral thrombectomy
  • Cerebral aneurysm and AVM surgical clipping
  • Cerebral aneurysm and AVM coiling & flow diversion
  • Congenital heart defect repair
  • Heart valve repair and replacement surgery
  • Transcatheter valve repair and replacement
  • Pacemaker implantation
  • Implantable cardioverter defibrillator placement
  • Cardiac resynchronization therapy device placement
  • Standard SVT ablation
  • Surgical AFib ablation
  • Transcatheter AFib ablation

These procedures are the subject of the August 2016 report, “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022” (report #C500).